Cartesian Therapeutics, Inc.
NASDAQ:RNACBiotechnology
-$0.41 today
- Market cap
- $186.68M
- Beta
- 0.78
- P/E (TTM)
- -1.7
- EPS (TTM)
- -$5.65
Volume 0.23M
Average 0.26M
Income Statement
Follow revenue through to earnings.
Revenue
$2.80M
FY 2025 · Annual
-92.8% YoYOperating Income
-$86.70M
FY 2025 · Annual
Net Income
-$130.30M
FY 2025 · Annual
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 85.08M | 110.78M | 26M | 38.91M | 2.8M |
| Cost of Revenue | 0 | 2.04M | 0 | 0 | 0 |
| Gross Profit | 85.08M | 108.74M | 26M | 38.91M | 2.8M |
| Gross Margin | 100.0% | 98.2% | 100.0% | 100.0% | 100.0% |
| Research & Development | 68.74M | 72.38M | 71.26M | 45.11M | 58.03M |
| Selling, General & Admin | 20.94M | 23.86M | 40.45M | 30.13M | 31.47M |
| Operating Expenses | 89.67M | 94.2M | 112.42M | 82.81M | 89.5M |
| Depreciation & Amortization | 1.72M | 2.04M | 843K | 1.15M | 2.96M |
| EBITDA | (5.16M) | 39.84M | (235.03M) | (75.99M) | (136.54M) |
| EBITDA Margin | -6.1% | 36.0% | -903.8% | -195.3% | -4881.5% |
| Operating Income | (4.6M) | 14.54M | (86.42M) | (43.9M) | (86.71M) |
| Operating Margin | -5.4% | 13.1% | -332.3% | -112.8% | -3099.9% |
| Interest Income | 0 | 0 | 4.96M | 7.39M | 6.58M |
| Interest Expense | 2.84M | 3.03M | 2.83M | 0 | 0 |
| Other Income / Expenses | (5.12M) | 20.23M | (152.29M) | (33.24M) | (52.79M) |
| Income Before Tax | (9.72M) | 34.77M | (238.71M) | (77.14M) | (139.5M) |
| Pre-Tax Margin | -11.4% | 31.4% | -918.0% | -198.2% | -4987.3% |
| Income Tax Expense | 15.97M | (609K) | (19M) | 287K | (9.19M) |
| Net Income | (25.69M) | 35.38M | (219.71M) | (77.42M) | (130.3M) |
| Net Margin | -30.2% | 31.9% | -844.9% | -199.0% | -4658.6% |
| EPS (Basic) | (6.74) | 7.33 | (49.76) | (2.99) | (5.02) |
| EPS (Diluted) | (6.60) | 3.00 | (49.76) | (3.29) | (5.02) |
| 3.18M | 4.02M | 5.17M | 25.91M | 25.97M | |
| 3.18M | 4.05M | 5.17M | 23.69M | 25.97M |
RNAC Earnings Waterfall · TTM
NASDAQ:RNAC · Revenue to Net Income
Key Ratios
Analysis
$1.8M of revenue converted into -$151.8M of net income for the selected period. Gross margin is -607.8% and net margin is -15655.3%, showing how much revenue survives after costs and taxes. EPS is $-5.70, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G/A | SC 13G/A filing | Nov 6, 2026 | |
| 8-K | Current report | Nov 5, 2026 | |
| 10-Q | Quarterly report | Nov 5, 2026 | |
| 8-K | Current report | Sep 29, 2026 | |
| SC 13G | SC 13G filing | Aug 13, 2026 |
How much revenue does RNAC generate?
Cartesian Therapeutics, Inc. (RNAC) reported $2.80M of revenue in fiscal 2025.
Is RNAC profitable?
Cartesian Therapeutics, Inc. (RNAC) reported -$130.30M of net income, with a net margin of -4658.6%.
Continue the stock analysis
Jump to another research area for this company.